Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03858075 | Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults | PHASE1 | COMPLETED | 108 | — | — | Feb 12, 2019 | Sep 11, 2019 | Nov 8, 2019 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Single ascending doses with BLU-782 | EXPERIMENTAL | - |
| Single ascending doses with placebo | PLACEBO_COMPARATOR | - |
| Multiple ascending doses with BLU-782 | EXPERIMENTAL | - |
| Multiple ascending doses with placebo | PLACEBO_COMPARATOR | - |
| Food effect of BLU-782 taken with food | EXPERIMENTAL | - |
| Food effect of BLU-782 taken without food | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BLU-782 | DRUG | oral capsules |
| Placebo | DRUG | oral capsules |
| BLU-782 taken with food | DRUG | oral capsules |
Inclusion Criteria: * Medically healthy * Non-smoker * Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2 * No clinically significant cardiac history * No current electrocardiogram (ECG) abnormality * Female must not be of childbearing potential Exclusion Criteria: * History of or current mental or legal ...